Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.
Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, Ciceri F, Oneto R, Bruno B, Martin PJ, Sandmaier BM, Storb R, Sorror ML. Vaughn JE, et al. Among authors: rambaldi a. Biol Blood Marrow Transplant. 2015 Aug;21(8):1418-24. doi: 10.1016/j.bbmt.2015.04.002. Epub 2015 Apr 7. Biol Blood Marrow Transplant. 2015. PMID: 25862589 Free PMC article.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Corradini P, et al. Among authors: rambaldi a. Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75. Blood. 2002. PMID: 11756155 Free article.
Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A; Gruppo Italiano Trapianto Midollo Osseo (GITMO). Falda M, et al. Among authors: rambaldi a. Am J Hematol. 2007 Oct;82(10):863-6. doi: 10.1002/ajh.20990. Am J Hematol. 2007. PMID: 17616972 Free article. Clinical Trial.
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: rambaldi a. J Clin Oncol. 2008 Jul 1;26(19):3166-75. doi: 10.1200/JCO.2007.14.4204. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490650
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Alessandrino EP, et al. Among authors: rambaldi a. Blood. 2008 Aug 1;112(3):895-902. doi: 10.1182/blood-2008-03-143735. Epub 2008 May 22. Blood. 2008. PMID: 18497321 Free article.
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.
Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Bruno B, et al. Among authors: rambaldi a. Blood. 2009 Apr 2;113(14):3375-82. doi: 10.1182/blood-2008-07-167379. Epub 2008 Dec 8. Blood. 2009. PMID: 19064724 Free PMC article. Clinical Trial.
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Among authors: rambaldi a. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.
Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A. Alessandrino EP, et al. Among authors: rambaldi a. Haematologica. 2010 Mar;95(3):476-84. doi: 10.3324/haematol.2009.011429. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903678 Free PMC article.
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E. Lucchini G, et al. Among authors: rambaldi a. Biol Blood Marrow Transplant. 2010 Sep;16(9):1293-301. doi: 10.1016/j.bbmt.2010.03.017. Epub 2010 Mar 27. Biol Blood Marrow Transplant. 2010. PMID: 20350611 Free article.
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: rambaldi a. J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189387
718 results